A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

  • End date
    Feb 10, 2023
  • participants needed
  • sponsor
    Eli Lilly and Company
Updated on 12 September 2021


The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.

Condition Chronic Heart Failure With Reduced Ejection Fraction
Treatment Placebo, LY3461767
Clinical Study IdentifierNCT04840914
SponsorEli Lilly and Company
Last Modified on12 September 2021


Yes No Not Sure

Inclusion Criteria

Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential
Have a body mass index (BMI) of < 40.0 kilograms per square meter (kg/m)
Have chronic stable heart failure (New York Heart Association (NYHA) classification II and III) on guideline directed heart failure therapy for at least 6 months prior to enrolment
Have not changed optimal guideline directed therapy in the last 1 month prior to screening, If treated with oral diuretics, dose must be stable for at least 2 weeks prior to screening
Have Left Ventricular Ejection Fraction (LVEF) < 40%
Have a record of N-terminal pro b-type natriuretic peptide (NT-ProBNP) 300 picograms per millilitre (pg/mL)

Exclusion Criteria

Have myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke in the last 90 days prior to screening
Have acute decompensated heart failure requiring IV diuretics within 12 weeks prior to screening
Have cardiac amyloidosis, accumulation diseases (e.g., haemochromatosis, Fabry disease), muscular dystrophies, hypertrophic cardiomyopathy, pericardial constriction, or complex congenital heart disease
Have any moderate-to-severe stenosis of the mitral and/or aortic valve or moderate-to severe or greater mitral and/or aortic regurgitation
Have a history or presence of hepatic, pancreatic, or biliary tract disorders
Have a history of malignancy or active malignancy at screening
Have not had age-appropriate cancer screening as recommended by the American Cancer Society and per medical judgment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note